U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H27F2N5O4
Molecular Weight 487.4991
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PEMIGATINIB

SMILES

CCN1C(=O)N(CC2=C1C3=C(NC(CN4CCOCC4)=C3)N=C2)C5=C(F)C(OC)=CC(OC)=C5F

InChI

InChIKey=HCDMJFOHIXMBOV-UHFFFAOYSA-N
InChI=1S/C24H27F2N5O4/c1-4-30-21-14(11-27-23-16(21)9-15(28-23)13-29-5-7-35-8-6-29)12-31(24(30)32)22-19(25)17(33-2)10-18(34-3)20(22)26/h9-11H,4-8,12-13H2,1-3H3,(H,27,28)

HIDE SMILES / InChI
Pemigatinib, an oral kinases inhibitor, was approved under the brand name PEMAZYRE for the treatment of adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion. The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. The drug inhibited FGFR1-3 phosphorylation and signaling and decreased cell viability in cancer cell lines with activating FGFR amplification and fusions that resulted in constitutive activation of FGFR signaling.

CNS Activity

Curator's Comment: pemigatinib crossed the blood-brain barrier at low levels after IV administration.

Originator

Curator's Comment: was synthesized at Incyte Corporation (Wilmington, DE).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P11362|||Q14307|||Q9UDF2
Gene ID: 2260.0
Gene Symbol: FGFR1
Target Organism: Homo sapiens (Human)
0.4 nM [IC50]
Target ID: P21802|||Q14301|||Q1KHY5|||Q9NZU3|||Q9UIH8
Gene ID: 2263.0
Gene Symbol: FGFR2
Target Organism: Homo sapiens (Human)
0.5 nM [IC50]
1.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PEMAZYRE

Approved Use

PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion

Sample Use Guides

The recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy, in 21-day cycles. Continue treatment until disease progression or unacceptable toxicity occurs
Route of Administration: Oral
Name Type Language
PEMIGATINIB
INN   USAN  
Official Name English
3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-8-(MORPHOLIN-4-YLMETHYL)-1,3,4,7-TETRAHYDRO-2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE
Systematic Name English
INCB-054828
Common Name English
PEMIGATINIB [USAN]
Common Name English
PEMIGATINIB [JAN]
Common Name English
Pemigatinib [WHO-DD]
Common Name English
PEMIGATINIB [ORANGE BOOK]
Common Name English
FGFR INHIBITOR INCB054828
Common Name English
pemigatinib [INN]
Common Name English
PEMIGATINIB [MI]
Common Name English
INCB054828
Code English
2H-PYRROLO(3',2':5,6)PYRIDO(4,3-D)PYRIMIDIN-2-ONE, 3-(2,6-DIFLUORO-3,5-DIMETHOXYPHENYL)-1-ETHYL-1,3,4,7-TETRAHYDRO-8-(4-MORPHOLINYLMETHYL)-
Systematic Name English
PEMAZYRE
Brand Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 624117
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
FDA ORPHAN DRUG 696419
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
EU-Orphan Drug EU/3/18/2066
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
NCI_THESAURUS C1967
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
Code System Code Type Description
INN
10712
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
CAS
1513857-77-6
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
MERCK INDEX
m12200
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
PUBCHEM
86705695
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
SMS_ID
100000181126
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
RXCUI
2359268
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
DRUG BANK
DB15102
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
USAN
FG-16
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
DRUG CENTRAL
5390
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
FDA UNII
Y6BX7BL23K
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
EPA CompTox
DTXSID501027955
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
DAILYMED
Y6BX7BL23K
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
WIKIPEDIA
Pemigatinib
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY
NCI_THESAURUS
C121553
Created by admin on Sat Dec 16 12:06:12 UTC 2023 , Edited by admin on Sat Dec 16 12:06:12 UTC 2023
PRIMARY